Surgery Ebitda from 2010 to 2024

SGRY Stock  USD 23.39  0.38  1.65%   
Surgery Partners EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about 289.1 M in 2024. During the period from 2010 to 2024, Surgery Partners EBITDA regression line of annual values had r-squared of  0.81 and arithmetic mean of  239,186,903. View All Fundamentals
 
EBITDA  
First Reported
2014-03-31
Previous Quarter
119.6 M
Current Value
111.1 M
Quarterly Volatility
46 M
 
Yuan Drop
 
Covid
Check Surgery Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Surgery Partners' main balance sheet or income statement drivers, such as Depreciation And Amortization of 80.6 M, Interest Expense of 148.4 M or Selling General Administrative of 80.8 M, as well as many indicators such as Price To Sales Ratio of 1.52, Dividend Yield of 0.0014 or PTB Ratio of 2.12. Surgery financial statements analysis is a perfect complement when working with Surgery Partners Valuation or Volatility modules.
  
Check out the analysis of Surgery Partners Correlation against competitors.
For more information on how to buy Surgery Stock please use our How to Invest in Surgery Partners guide.

Latest Surgery Partners' Ebitda Growth Pattern

Below is the plot of the Ebitda of Surgery Partners over the last few years. It is Surgery Partners' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Surgery Partners' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Surgery Ebitda Regression Statistics

Arithmetic Mean239,186,903
Geometric Mean191,458,832
Coefficient Of Variation61.29
Mean Deviation123,398,056
Median254,775,000
Standard Deviation146,593,968
Sample Variance21489.8T
Range408.3M
R-Value0.90
Mean Square Error4416.4T
R-Squared0.81
Slope29,486,335
Total Sum of Squares300857.1T

Surgery Ebitda History

2024289.1 M
2023480.8 M
2022460 M
2021401 M
2020277.8 M
2019344.4 M
2018329.1 M

About Surgery Partners Financial Statements

Surgery Partners investors use historical fundamental indicators, such as Surgery Partners' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Surgery Partners. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA480.8 M289.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Surgery Stock Analysis

When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.